How Researchers Wiped Out Triple-Negative Breast Cancer
Triple-negative breast cancer is a fast-growing form of the disease that tends to return (recur). But a fresh therapeutic approach was found to be capable of eliminating the disease altogether.
Powerwashing HER2+ Breast Cancer
HER2-positive breast cancer is an aggressive disease that thankfully can be treated with targeted therapies. A new combination regimen was successful in keeping patients in a recent trial disease free.
Breast Cancer Drug Controversy Continues
Cancer tumors need an entire support structure of blood vessels to get the nutrients it needs to survive. A drug that goes after the support structure in metastatic breast cancer slows the progression of the disease, but doesn't prolong life.
Advancements in Treating Advanced Breast Cancers
A great deal of exciting news has been released recently regarding novel drug combinations that extend the lives of patients living with advanced breast cancers.
FDA Revokes Approval of Breast Cancer Drug
FDA Commissioner Margaret A. Hamburg, MD, said she is revoking the agency’s approval of the breast cancer indication for Avastin ( bevacizumab ) after concluding that the drug has not been shown to be safe and effective for that use.
FDA Panel Rules Against Avastin - Again
In an unprecedented appeals hearing, the US Food and Drug Administration (FDA) has not changed its mind. An FDA panel voted that the drug Avastin no longer be approved for treating late-stage breast cancers.
Avastin Will Still be Covered
Even though a U.S. Food and Drug Administration (FDA) panel has voted to no longer approve Avastin ( bevacizumab ) for treating late-stage breast cancers, Medicare has indicated it will continue to pay for the drug.
FDA to Determine Fate of Breast Cancer Drug - Again
In a first ever hearing, the U.S. Food and Drug Administration is considering reversing itself on a ruling to withdraw Avastin as a drug to treat metastatic (spread outside of the primary affected organ) breast cancer.